




Figures to know about the 2023 metastatic Breast Cancer database



Selection criteria

- Female or male patients
- ≥18 years old
- with mBC whose first metastatic event was treated (completely or partially) in a French Comprehensive Cancer Center

Selection period: 2008-2021

Database extracted in 2023

De novo / relapsed

10 843

patients with **de novo mBC**

21 755

patients with **relapsed mBC**

Metastatic disease

At mBC diagnosis

7 033 patients
with 3 or more metastatic sites

Visceral
14 241
(44%)

CNS
2 166
(7%)

Bone
8 540
(26%)

Other site
15 267
(47%)

32 598 patients with
metastatic breast cancer (mBC)


♂ **281**

♀ **32 317**

HR / HER2 profiles

Global IHC profile determined:

- within 3 months from mBC diagnosis or
- at primary tumor if not available at mBC diagnosis



BRCA testing

5 845 patients
have undergone **BRCA testing**

► **527** patients with a **germline BRCA mutation**

Follow-up

Median follow-up 89.4 months

According to reverse Kaplan-Meier Method

Minimum estimated follow-up

- 36 months for 28 600 patients
- 60 months for 22 900 patients